Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty.
Author(s): O'Keefe JH Jr, Stone GW, McCallister BD Jr, Maddex C, Ligon R, Kacich RL, Kahn J, Cavero PG, Hartzler GO, McCallister BD
Affiliation(s): Mid America Heart Institute, St. Luke's Hospital, Kansas City, Missouri, USA.
Publication date & source: 1996-03-15, Am J Cardiol., 77(8):649-52.
Publication type: Clinical Trial; Randomized Controlled Trial
Combination lovastatin and probucol reduced total cholesterol (27%) and low-density lipoprotein levels (30%), but did not prevent restenosis or clinical events during the first 6 months after percutaneous transluminal coronary angioplasty.
|